Donald Emil Ganem
Amministratore Delegato presso Via Nova Therapeutics, Inc.
Posizioni attive di Donald Emil Ganem
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Via Nova Therapeutics, Inc.
 Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Direttore/Membro del Consiglio | - | - |
| Amministratore Delegato | - | - | |
| Presidente | - | - |
Storia della carriera di Donald Emil Ganem
Statistiche
Distribuzione geografica
| Stati Uniti | 2 |
Posizioni
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
| President | 1 |
Settori
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 1 |
|---|---|
Via Nova Therapeutics, Inc.
Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Health Technology |
- Borsa valori
- Insiders
- Donald Emil Ganem
- Esperienza
